http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108187069-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 |
| filingDate | 2018-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108187069-B |
| titleOfInvention | A kind of voriconazole pharmaceutical composition and its preparation |
| abstract | The invention belongs to biomedicine technical fields, and in particular to a kind of voriconazole pharmaceutical composition and its preparation, pharmaceutical composition composition are as follows: voriconazole, hydroxypropyl-β-cyclodextrin, glycine, 2mol/L hydrochloric acid solution, sodium bicarbonate；Research shows that, the degree of substitution of hydroxypropyl-β-cyclodextrin is that the voriconazole purity variation of 3.80-4.80 inclusion is small, the powder-injection being prepared into is after cold cycling, particulate matter number is well below the upper limit as defined in standards of pharmacopoeia, stability study shows that invention formulation has superior product quality. |
| priorityDate | 2018-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 91.